Mesa Verde Venture Partners

CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D, who identified Orai1 as the CRAC channel subunit in 2006.

Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.

Lineagen, Inc. operates as a genetics diagnostic company that focuses on genetic testing and clinical information services for various neurodevelopmental disorders. It offers FirstStepDx PLUS, a chromosomal microarray platform that is optimized to detect genomic changes associated with autism and neurodevelopmental disorders; NextStepDx PLUS, a genetic sequencing test to detect small changes in the genome; and M-CHAT.org, an online screening tool for physicians and parents to assess developmental evaluation, such as ADI/ADOS. It serves healthcare professionals, physicians, and individuals. Lineagen, Inc. was formerly known as GenData Research Corporation and changed its name to Lineagen, Inc. in January 2003. The company was founded in 2002 and is based in Salt Lake City, Utah. As of August 21, 2020, Lineagen, Inc. operates as a subsidiary of Bionano Genomics, Inc.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D, who identified Orai1 as the CRAC channel subunit in 2006.

Immusoft Corporation operates as a biotechnology company that develops an autologous cell therapy platform for treating various human diseases through its Immune System Programming (ISP) technology. The company develops protein therapeutics using a patient's cells. Its technology enables the in vivo delivery of gene-encoded medicines (biologics) by re-programming the patient’s cells to replace missing or defective enzymes and proteins. The company was founded in 2009 and is based in Seattle, Washington.

Paradigm Diagnostics, Inc. provides diagnostics and biomarker driven clinical trial services for cancer patients. The company offers PCDx test that provides patients and physicians with a blueprint of the underlying mechanisms of a patient’s disease, potential treatment approaches, and inventory of relevant clinical trials, as well as assesses clinically-actionable genomic variations in cancer, including mutations, copy number variations, mRNA expression, and protein expression. It also offers BioPharma services, which include personalized clinical trial assays, biorepository consultation, molecular services, nucleic acid isolation, and laser capture enrichment, as well as bio specimen collection, storage, processing, and analysis services. The company was founded in 2012 and is based in Phoenix, Arizona. As of March 3, 2020, Paradigm Diagnostics, Inc. operates as a subsidiary of Exact Sciences Corporation.

Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.

Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment.

Biscayne Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops therapies based on growth hormone-releasing hormone (GHRH) analogs. The compounds include GHRH antagonists in development for the treatment of cancer, including castrate-resistant prostate cancer, and GHRH agonists for the repair of cardiac damage in heart disease patients. The company was incorporated in 2012 and is headquartered in Miami, Florida.

Lineagen, Inc. operates as a genetics diagnostic company that focuses on genetic testing and clinical information services for various neurodevelopmental disorders. It offers FirstStepDx PLUS, a chromosomal microarray platform that is optimized to detect genomic changes associated with autism and neurodevelopmental disorders; NextStepDx PLUS, a genetic sequencing test to detect small changes in the genome; and M-CHAT.org, an online screening tool for physicians and parents to assess developmental evaluation, such as ADI/ADOS. It serves healthcare professionals, physicians, and individuals. Lineagen, Inc. was formerly known as GenData Research Corporation and changed its name to Lineagen, Inc. in January 2003. The company was founded in 2002 and is based in Salt Lake City, Utah. As of August 21, 2020, Lineagen, Inc. operates as a subsidiary of Bionano Genomics, Inc.

Lineagen, Inc. operates as a genetics diagnostic company that focuses on genetic testing and clinical information services for various neurodevelopmental disorders. It offers FirstStepDx PLUS, a chromosomal microarray platform that is optimized to detect genomic changes associated with autism and neurodevelopmental disorders; NextStepDx PLUS, a genetic sequencing test to detect small changes in the genome; and M-CHAT.org, an online screening tool for physicians and parents to assess developmental evaluation, such as ADI/ADOS. It serves healthcare professionals, physicians, and individuals. Lineagen, Inc. was formerly known as GenData Research Corporation and changed its name to Lineagen, Inc. in January 2003. The company was founded in 2002 and is based in Salt Lake City, Utah. As of August 21, 2020, Lineagen, Inc. operates as a subsidiary of Bionano Genomics, Inc.

Zavante Therapeutics, Inc., a biopharmaceutical company, engages in developing medicines for the treatment of diseases that affect patients in the hospital setting. Its products in pipeline include ZOLYD, an investigational injectable antibiotic under development to combat serious and life-threatening infections, including those due to multi-drug resistant gram-negative and gram-positive bacteria. The company was incorporated in 2013 and is based in San Diego, California. As of July 24, 2018, Zavante Therapeutics, Inc. operates as a subsidiary of Nabriva Therapeutics plc.

Elysium Therapeutics is a health care company that focuses on biotechnology, fitness, medical, and robotics. It was founded in 2013 and headquartered in Danville, California.

Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment.

Biscayne Neurotherapeutics is a clinical-stage biotechnology company developing novel therapies for difficult-to-treat neurological disorders. Biscayne’s lead compound, BIS-001, is in clinical development for the treatment of refractory forms of epilepsy. Biscayne Neurotherapeutics has an experienced executive team with an extensive track record of successful drug development, and its scientific advisors include a number of highly respected experts studying seizure and other CNS disorders. The company is headquartered in Miami, Florida, and benefits from the growing entrepreneurial South Florida biomedical sector.

Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.

Immusoft Corporation operates as a biotechnology company that develops an autologous cell therapy platform for treating various human diseases through its Immune System Programming (ISP) technology. The company develops protein therapeutics using a patient's cells. Its technology enables the in vivo delivery of gene-encoded medicines (biologics) by re-programming the patient’s cells to replace missing or defective enzymes and proteins. The company was founded in 2009 and is based in Seattle, Washington.

Immusoft Corporation operates as a biotechnology company that develops an autologous cell therapy platform for treating various human diseases through its Immune System Programming (ISP) technology. The company develops protein therapeutics using a patient's cells. Its technology enables the in vivo delivery of gene-encoded medicines (biologics) by re-programming the patient’s cells to replace missing or defective enzymes and proteins. The company was founded in 2009 and is based in Seattle, Washington.

Immix Biopharma's mission is to develop novel and game-changing cancer therapies.

Medipacs, Inc. develops non-mechanical infusion pumps used to deliver drugs, including biologic medications, insulin, hormones, fertility drugs, anti-coagulation drugs, and pain medication. The company was founded in 2004 and is based in San Diego, California with research facilities in Tucson, Arizona.

Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.

Lineagen, Inc. operates as a genetics diagnostic company that focuses on genetic testing and clinical information services for various neurodevelopmental disorders. It offers FirstStepDx PLUS, a chromosomal microarray platform that is optimized to detect genomic changes associated with autism and neurodevelopmental disorders; NextStepDx PLUS, a genetic sequencing test to detect small changes in the genome; and M-CHAT.org, an online screening tool for physicians and parents to assess developmental evaluation, such as ADI/ADOS. It serves healthcare professionals, physicians, and individuals. Lineagen, Inc. was formerly known as GenData Research Corporation and changed its name to Lineagen, Inc. in January 2003. The company was founded in 2002 and is based in Salt Lake City, Utah. As of August 21, 2020, Lineagen, Inc. operates as a subsidiary of Bionano Genomics, Inc.

Lineagen, Inc. operates as a genetics diagnostic company that focuses on genetic testing and clinical information services for various neurodevelopmental disorders. It offers FirstStepDx PLUS, a chromosomal microarray platform that is optimized to detect genomic changes associated with autism and neurodevelopmental disorders; NextStepDx PLUS, a genetic sequencing test to detect small changes in the genome; and M-CHAT.org, an online screening tool for physicians and parents to assess developmental evaluation, such as ADI/ADOS. It serves healthcare professionals, physicians, and individuals. Lineagen, Inc. was formerly known as GenData Research Corporation and changed its name to Lineagen, Inc. in January 2003. The company was founded in 2002 and is based in Salt Lake City, Utah. As of August 21, 2020, Lineagen, Inc. operates as a subsidiary of Bionano Genomics, Inc.

Founded in 2016, NeuraLace is a technology company with a focus on medical innovations. The company is developing a non-invasive interface, bridging the gap between technology and neurology, to deliver sustainable chronic pain relief at scale.

Immusoft Corporation operates as a biotechnology company that develops an autologous cell therapy platform for treating various human diseases through its Immune System Programming (ISP) technology. The company develops protein therapeutics using a patient's cells. Its technology enables the in vivo delivery of gene-encoded medicines (biologics) by re-programming the patient’s cells to replace missing or defective enzymes and proteins. The company was founded in 2009 and is based in Seattle, Washington.

Immix Biopharma's mission is to develop novel and game-changing cancer therapies.